Arbutus Biopharma
ABUS
119 hedge funds and large institutions have $215M invested in Arbutus Biopharma in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 13 closing their positions.
688% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $1.63M
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
6% more funds holding
Funds holding: 112 → 119 (+7)
0% more capital invested
Capital invested by funds: $215M → $215M (+$374K)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4.77% less ownership
Funds ownership: 51.24% → 46.47% (-4.8%)
14% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 36
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.77M |
| 2 |
BCP
BlackBarn Capital Partners
New York
|
+$5.36M |
| 3 |
FCM
FourWorld Capital Management
New York
|
+$4.95M |
| 4 |
CCP
Corbin Capital Partners
New York
|
+$2.21M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.17M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$13.3M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$3.61M |
| 3 |
Millennium Management
New York
|
-$3.36M |
| 4 |
TSC
Two Seas Capital
Rye,
New York
|
-$3.11M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.04M |
ABUS Hedge Fund Activity: Q1 2024 in Review
119 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2024, worth a combined $215M — up 0.17% from $215M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ABUS positions and 13 closed out — a net gain of 7 holders — while 31 added to existing stakes and 36 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $7.77M. The largest seller was Morgan Stanley, cutting an estimated $13.3M.
- 119 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2024, up from 112 in Q4 2023.
- Funds reported $215M of Arbutus Biopharma stock for Q1 2024, up 0.17% quarter-over-quarter.
- 20 funds opened new Arbutus Biopharma positions in Q1 2024 and 13 closed out, a net change of +7 holders.
- The largest Arbutus Biopharma buyer in Q1 2024 was Adage Capital Partners, an estimated $7.77M added.
- The largest Arbutus Biopharma seller in Q1 2024 was Morgan Stanley, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2024.